Latest Share Chat

REMOVE ADS

Hutchmed Share News (HCM)

Hutchmed Information

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes

Get Live Data

168.00 3.25 (1.97%)

Bid:

158.50

Ask:

167.50

Spread: 9.00 (5.678%)

Market Cap: £1.44b

Last checked at -

Intraday Hutchmed Share Chart

REMOVE ADS

Hutchmed News

AIM WINNERS & LOSERS: Hutchmed up on positive results for cancer drug

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Hutchmed reports positive results from recent fruquintinib study

(Sharecast News) - Hutchmed China announced initial results from the 'FRUTIGA' phase 3 study of fruquintinib combined with paclitaxel in 703 Chinese p...

IN BRIEF: Hutchmed begins phase II/III trial of fruquintinib

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Begins randomised, open-label, active-controlled phase II/III trial of fruquintinib c...

Hutchmed begins sovleplenib trial for anaemia treatment in China

(Alliance News) - Hutchmed China Ltd on Monday said it has begun a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmune h...

Hutchmed posts positive results for CRC cancer treatment

(Alliance News) - Hutchmed China Ltd on Thursday said that its fruquintinib treatment reduced risk of death by 34% in metastatic colorectal cancer pat...

Hutchmed notes dosing of first participant in IMG-004 study

(Alliance News) - Hutchmed China Ltd on Tuesday said it has dosed its first participant in its global phase one trial of IMG-004.

Hutchmed upbeat on latest study results for colorectal cancer treatment

(Sharecast News) - Hutchmed China announced on Monday that the "pivotal" global phase three trial evaluating the investigational use of 'fruquintinib'...

UPDATE: Hutchmed, AstraZeneca move lung cancer drug to phase 3 trial

(Alliance News) - Hutchmed China Ltd and AstraZeneca PLC on Monday said preliminary results from the Savannah phase 2 trial showed a promising objecti...